Skip to main content

Table 2 Susceptibility testing results for isolated A. baumannii

From: Efficacy of intravenous plus intrathecal/intracerebral ventricle injection of polymyxin B for post-neurosurgical intracranial infections due to MDR/XDR Acinectobacter baumannii: a retrospective cohort study

  MIC
Break-point
Total ITV group ITV + ITC group  
(mg/L) (n = 61) (n = 38) (n = 23) P
Antibiotic resistance (n, %)      0.402
Amikacin R ≥ 32 25, 40.98% 12, 31.58% 13, 56.52%  
Tigecycline R ≥ 8 3, 2.92% 2, 5.26% 1, 4.35%  
Carbapenems
 Imipenem R ≥ 8 60, 98.36% 37, 97.36% 23, 100.00%  
 Meropenem R ≥ 8 60, 98.36% 37, 97.36% 23, 100.00%  
Cephalosporins
 Cefazolin R ≥ 32 60, 98.36% 38, 100.00% 22, 95.65%  
 Ceftazidime R ≥ 32 60, 98.36% 37, 97.36% 23, 100.00%  
 Cefatriaxone R ≥ 64 61, 100.00% 38, 100.00% 23, 100.00%  
 Cefepime R ≥ 32 60, 98.36% 37, 97.36% 23, 100.00%  
 Polymyxin B R ≥ 4 0, 0.00% 0, 0.00% 0, 0.00%  
  1. ITV intravenous, ITV + ITC intrathecal/intracerebral